Calithera Biosciences, Inc. (NASDAQ:CALA) is a clinical‐stage biopharmaceutical company focused on the discovery and development of small‐molecule therapies that target tumor metabolism and the tumor microenvironment. Leveraging proprietary research in amino acid and energy metabolism, Calithera aims to disrupt key metabolic pathways that support cancer cell growth and immune evasion. The company’s approach seeks to enhance anti-tumor immunity while directly impairing the metabolic processes that tumors rely upon for survival and proliferation.
The company’s pipeline features multiple preclinical and clinical‐stage programs, including inhibitors of arginase, glutaminase, and other enzymes critical to cancer metabolism. Its lead candidates are being evaluated in various solid tumors and hematologic malignancies, both as monotherapies and in combination with established immuno-oncology agents. Through strategic collaborations with academic institutions and larger pharmaceutical partners, Calithera advances its compounds through regulatory milestones with the goal of addressing treatment-resistant cancers.
Headquartered in South San Francisco, California, Calithera maintains a lean organizational structure supported by research facilities in the Bay Area. The company conducts its clinical trials primarily in North America but also collaborates with international sites in Europe and Asia to access diverse patient populations. Its translational research teams work closely with external investigators to optimize dosing regimens and identify biomarkers that may predict patient response and support regulatory submissions.
Founded in 2007, Calithera has been led since 2018 by President and Chief Executive Officer Jackie Fouse, whose background spans oncology drug development and global program management. The management team combines expertise in medicinal chemistry, clinical operations, and commercial strategy. With a board of directors that includes seasoned biotech entrepreneurs and institutional investors, Calithera is positioned to advance its metabolic immunotherapy platform toward late‐stage development and potential regulatory approval.
AI Generated. May Contain Errors.
Free CALA Stock Alerts